EE200100187A - Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga - Google Patents

Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Info

Publication number
EE200100187A
EE200100187A EEP200100187A EEP200100187A EE200100187A EE 200100187 A EE200100187 A EE 200100187A EE P200100187 A EEP200100187 A EE P200100187A EE P200100187 A EEP200100187 A EE P200100187A EE 200100187 A EE200100187 A EE 200100187A
Authority
EE
Estonia
Prior art keywords
acetyldinaline
capecitabine
gemcitabine
cisplatin
combination
Prior art date
Application number
EEP200100187A
Other languages
English (en)
Estonian (et)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200100187A publication Critical patent/EE200100187A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EEP200100187A 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga EE200100187A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (en) 1998-09-25 1999-07-08 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin

Publications (1)

Publication Number Publication Date
EE200100187A true EE200100187A (et) 2002-08-15

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100187A EE200100187A (et) 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Country Status (34)

Country Link
US (3) US6469058B1 (xx)
EP (1) EP1115391B1 (xx)
JP (1) JP2002525320A (xx)
KR (1) KR20010075348A (xx)
CN (1) CN1319009A (xx)
AP (1) AP2001002109A0 (xx)
AT (1) ATE225655T1 (xx)
AU (1) AU762079B2 (xx)
BG (1) BG105470A (xx)
BR (1) BR9913952A (xx)
CA (1) CA2342981A1 (xx)
CZ (1) CZ2001905A3 (xx)
DE (1) DE69903458T2 (xx)
DK (1) DK1115391T3 (xx)
EA (1) EA200100369A1 (xx)
EE (1) EE200100187A (xx)
ES (1) ES2185378T3 (xx)
GE (1) GEP20043199B (xx)
HK (1) HK1040190A1 (xx)
HR (1) HRP20010225B1 (xx)
HU (1) HUP0103640A3 (xx)
ID (1) ID30046A (xx)
IL (1) IL141951A0 (xx)
IS (1) IS5888A (xx)
NO (1) NO20011493L (xx)
NZ (1) NZ510504A (xx)
OA (1) OA11659A (xx)
PL (1) PL348673A1 (xx)
PT (1) PT1115391E (xx)
SK (1) SK3602001A3 (xx)
TR (1) TR200100859T2 (xx)
WO (1) WO2000018393A1 (xx)
YU (1) YU22401A (xx)
ZA (1) ZA200102233B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
NZ550185A (en) * 2002-03-04 2008-10-31 Merck Hdac Res Llc Methods of inducing terminal differentiation Methods of inducing terminal differentiation
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CA2482508A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
CA2506085A1 (en) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
EP1643971A2 (en) * 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
ATE507879T1 (de) 2005-07-22 2011-05-15 Tomotherapy Inc System zur verabreichung einer strahlentherapie auf ein sich bewegendes zielgebiet
CA2616292A1 (en) * 2005-07-22 2007-02-01 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treament plan
EP1907981A4 (en) * 2005-07-22 2009-10-21 Tomotherapy Inc METHOD AND SYSTEM FOR DOSE EVALUATION ADMINISTERED
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
JP2009502251A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 放射線治療システムによって送達された線量を評価するシステム及び方法
JP2009502253A (ja) 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 関心の移動領域に対して放射線療法を施すシステムおよび方法
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
CN101534852B (zh) * 2006-08-31 2013-02-13 光谱医药公司 通过施用内皮素激动剂使得肿瘤细胞对放疗敏化
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
JO3197B1 (ar) 2009-04-06 2018-03-08 Otsuka Pharma Co Ltd (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
CN107469240B (zh) 2013-02-26 2020-04-21 安科锐公司 多叶准直器和用于准直治疗放射束的系统
US10189797B2 (en) * 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
AU6878198A (en) 1997-04-24 1998-11-13 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Also Published As

Publication number Publication date
US6469058B1 (en) 2002-10-22
PT1115391E (pt) 2003-02-28
AU762079B2 (en) 2003-06-19
CA2342981A1 (en) 2000-04-06
TR200100859T2 (tr) 2001-08-21
DK1115391T3 (da) 2003-02-10
WO2000018393A1 (en) 2000-04-06
IS5888A (is) 2001-03-14
ZA200102233B (en) 2002-06-18
NO20011493D0 (no) 2001-03-23
NO20011493L (no) 2001-05-23
HRP20010225A2 (en) 2002-04-30
ES2185378T3 (es) 2003-04-16
JP2002525320A (ja) 2002-08-13
HK1040190A1 (zh) 2002-05-31
EA200100369A1 (ru) 2001-10-22
YU22401A (sh) 2004-03-12
AU5092199A (en) 2000-04-17
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
DE69903458D1 (de) 2002-11-14
ATE225655T1 (de) 2002-10-15
CZ2001905A3 (cs) 2001-08-15
CN1319009A (zh) 2001-10-24
DE69903458T2 (de) 2003-07-10
ID30046A (id) 2001-11-01
AP2001002109A0 (en) 2001-03-31
US20030086965A1 (en) 2003-05-08
HRP20010225B1 (en) 2004-10-31
PL348673A1 (en) 2002-06-03
KR20010075348A (ko) 2001-08-09
NZ510504A (en) 2003-09-26
GEP20043199B (en) 2004-03-25
SK3602001A3 (en) 2002-07-02
BG105470A (en) 2001-12-29
OA11659A (en) 2004-12-08
US20030170300A1 (en) 2003-09-11
BR9913952A (pt) 2001-06-12
EP1115391B1 (en) 2002-10-09
HUP0103640A2 (en) 2002-06-29
EP1115391A1 (en) 2001-07-18

Similar Documents

Publication Publication Date Title
EE200100187A (et) Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga
PT1114031E (pt) 4-carboxiamino-1,2,3,4-tetradhiroquinolinas substituidas em posicao 2
NO20006520L (no) Adenosinderivater
IS5969A (is) Samsett lyfjameðferð
NL1011999A1 (nl) Trisresorcinyltriazinen.
NO20020394L (no) Parenteral cisplatinemulsjon
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
TR199900635A3 (tr) Pozitif kontrollü tüylendirme silindirleri içeren tüylendirme makinesi.
DE29621141U1 (de) Bekleidungsstück mit Taschen o.dgl.
FR2779658B1 (fr) Planche de glisse
DE29622842U1 (de) Bekleidungsstück mit Taschen o.dgl.
DE29808943U1 (de) Schiebetüranordnung
DE59904544D1 (de) Waffe, insbesondere panzerabwehrwaffe
DE29805832U1 (de) Mehrschichtiger, plattenförmiger Heizkörper
IT1305654B1 (it) Resistenze corazzate con guaina perfezionata.
DK9800114U3 (da) Jalousi-skab med oplukkelig bordarr. med integreret opslagstavle
BR8101035Y1 (pt) disposição introduzida em luminária de embutir.
ES1041848Y (es) Perfil frontal para cerraduras.
IT1304980B1 (it) Registro bidirezionale per porte,specialmente per porte blindate.
BR8202541Y1 (pt) aperfeiçoamento introduzido em bolsão.
ES1039731Y (es) Armario de seguridad.
ES1041380Y (es) Puerta acorazada perfeccionada.
DE29822118U1 (de) Elektronikrechner, insbesondere Taschenrechner